A liquid biopsy is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumour through a simple blood sample. Traces of the cancerโs DNA in the blood can give clues about which treatments are most likely to work for that patient.
A liquid biopsy test that can detect epidermal growth factor receptor (EGFR ) gene mutations, which occur in 10-35 per cent of patients with non-small cell lung cancer (NSCLC), will help doctors to choose the right treatment for the right patient at the right time.
Much of the early research on liquid biopsies has been in lung, breast and prostate cancers but this technology is expected to have an impact on all types of cancer.
๐๐ซ๐๐ ๐๐๐ ๐ฐ๐ข๐ญ๐ก ๐๐ฉ๐๐๐ญ๐๐ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ โย https://www.360marketupdates.com/enquiry/request-sample/22493078&piyush
The non-invasive nature of a liquid biopsies, which require only 5 millilitres of blood, means they are much easier to tolerate and the procedure is quicker than a surgical biopsy. The blood sample is then โspun downโ to get 2 millilitres of plasma which can be analysed for tumour DNA.
Tolerability and convenience are a major boost for patients. The biggest benefit lies in the potential of liquid biopsies to detect disease progression or treatment resistance long before it would trigger clinical symptoms or appear on imaging scans.
๐๐๐ฆ๐ฉ๐ฅ๐ข๐ง๐ ๐๐ฒ๐ฉ๐ ๐จ๐ ๐๐ข๐ช๐ฎ๐ข๐ ๐๐ข๐จ๐ฉ๐ฌ๐ฒ:-
* Blood Sampling Liquid Biopsy
* Urine Sampling Liquid Biopsy
* Salivaย Other Tissue Fluids Sampling Liquid Biopsy
๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐๐ฉ๐ฉ๐ฅ๐ข๐๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐๐ข๐ช๐ฎ๐ข๐ ๐๐ข๐จ๐ฉ๐ฌ๐ฒ:-
* Early Cancer Screening
* Therapy Selection
* Treatment Monitoring
* Recurrence Monitoring